Bedrijfsoverzicht
MediWound Ltd. is a biopharmaceutical entity dedicated to the development, manufacturing, and commercialization of novel bio-therapeutic and non-surgical solutions designed for tissue repair and regeneration across markets in the United States, Germany, Italy, Spain, and internationally. The company operates within the healthcare sector, specifically inside the biotechnology industry, which focuses on the discovery and production of biological products intended to treat or prevent disease. MediWound maintains a market capitalization of $229.41M and generated annual revenue of $16.96M over the trailing twelve months while employing a workforce of 121 individuals. These valuation and revenue figures indicate that the company functions as a mid-sized entity within the biotechnology landscape, currently generating limited sales relative to its market capitalization, a dynamic often observed in early-stage companies where market expectations may outpace current revenue realization.
Financiële gezondheid
The company reported a revenue of $16.96M for the trailing twelve months, yet posted a net income of $-23,879,000 and an EBITDA of $-24,280,000, revealing a significant disparity between top-line generation and bottom-line profitability. This substantial gap between revenue and net income highlights a cost structure where operating expenses and other charges exceed the gross profit generated from sales, resulting in a loss that is more than 1.3 times the size of the revenue stream. Free cash flow stands at $-15,578,875, indicating that the company is consuming cash reserves to fund its operations and development efforts rather than generating surplus liquidity for distribution or acquisitions. Gross margin is recorded at 19.2%, suggesting that the company retains just under one-fifth of its revenue as gross profit after direct costs. Operating margin is significantly negative at -417.8%, reflecting that operating expenses are more than four times the gross profit, while profit margin sits at -140.8%, confirming that the company is losing over 14 cents for every dollar of revenue. The balance sheet shows a cash position of $53.14M against total debt of $8.78M, resulting in a debt-to-equity ratio of 20.11, which implies a leveraged position relative to equity but maintains a conservative stance regarding absolute debt levels given the high cash buffer. A current ratio of 2.33 indicates strong short-term liquidity, suggesting the company holds sufficient current assets to cover its short-term liabilities more than twice over. Return on equity is -63.9% and return on assets is -19.8%, metrics that reveal management has not yet achieved positive returns on the capital invested or the assets utilized, consistent with the company's current loss-making status.
Waarderingsbeoordeling
The trailing twelve months P/E ratio is N/A due to negative earnings, whereas the forward P/E is listed at -8.23, implying that the market is currently pricing in a trajectory where earnings are expected to remain negative or are projected to improve only marginally in the near future. The price-to-book ratio stands at 5.25, indicating that the market values the company's equity at more than five times its book value, which suggests a significant market premium assigned to the company's intangible assets and future growth potential despite current losses. Price-to-sales is 13.53 and EV/EBITDA is -7.62, alternative valuation metrics that suggest the market is willing to pay a high multiple of sales revenue for the company's biotechnology pipeline, effectively ignoring current profitability to value future product potential. The stock has traded between a 52-week high of $22.50 and a 52-week low of $14.90, meaning the current price sits somewhere within this range, reflecting a volatility that has been contained within a relatively narrow band over the last year. The beta value is 0.15, indicating that the stock's price volatility is significantly lower than the broader market, behaving as a defensive or low-volatility instrument relative to the systemic movements of the overall equity market.
Growth & Income
Revenue growth year-over-year is -68.0%, while earnings growth is N/A, indicating that the company is currently experiencing a contraction in sales rather than expansion. The fact that earnings growth is not applicable while revenue is negative implies that the company is in a phase of scaling down or pivoting its commercial strategy rather than growing its top line. The company does not pay a dividend, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning the firm retains all available cash flow to reinvest into research, development, and commercialization efforts rather than distributing income to shareholders. This reinvestment strategy is typical for biotechnology companies in the development phase that prioritize capital expenditure on their product pipelines over immediate shareholder returns. The overall growth and income profile for MediWound is characterized by a contraction in revenue, a complete absence of dividend income, and a reliance on existing cash reserves to fund operations in the absence of positive earnings.